Malignancy Clinical Trials in Shanghai, Shanghai Municipality
9 recruitingShanghai, Shanghai Municipality, China
Showing 1–9 of 9 trials
Recruiting
Phase 1Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled127 locationsNCT05006716
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Not Applicable
Target-specific immunoPET Imaging of Digestive System Carcinoma
MalignancyLiver CancerPancreatic Cancer+12 more
RenJi Hospital400 enrolled1 locationNCT06715839
Recruiting
Phase 1
A Study of GLB-001 in Patients With Myeloid Malignancies
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelofibrosis+3 more
Hangzhou GluBio Pharmaceutical Co., Ltd.108 enrolled14 locationsNCT06378437
Recruiting
Phase 1Phase 2
A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies
Myeloid Malignancy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.138 enrolled21 locationsNCT07011186
Recruiting
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy
Hepatobiliary Malignancy
Ruijin Hospital40 enrolled1 locationNCT06597539
Recruiting
Phase 2
Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.
Myeloid MalignancyHypomethylating AgentVenetoclax
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine78 enrolled1 locationNCT05841771
Recruiting
Phase 1
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
Advanced Solid TumorHematological Malignancy
Shanghai Yuyao Biotech Co., Ltd.96 enrolled1 locationNCT06225856